Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

TCL-1B4 Inhibitors

TCL-1B4 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the TCL-1B4 gene and its associated proteins. TCL-1B4 is part of the TCL1 family, which is known for its involvement in intracellular signaling and the regulation of cellular processes such as proliferation and differentiation. The TCL-1 family proteins, including TCL-1B4, typically interact with key signaling molecules like kinases and phosphoinositide 3-kinase (PI3K) pathway components. TCL-1B4, in particular, is believed to modulate these signaling pathways, potentially influencing cell growth and survival. By inhibiting TCL-1B4, these compounds interfere with the molecular interactions that govern cellular signaling, leading to altered regulation of cell cycle processes and intracellular communication.

The use of TCL-1B4 inhibitors in research allows scientists to explore the functional role of TCL-1B4 in cellular signaling networks. By blocking its activity, researchers can study how the inhibition of this protein affects cellular pathways that are crucial for maintaining cell cycle progression, metabolism, and responses to environmental cues. Inhibiting TCL-1B4 provides insights into the protein's contributions to signal transduction and its role in regulating cellular homeostasis. Additionally, TCL-1B4 inhibitors are valuable tools for understanding how the TCL1 family of proteins interacts with other molecular pathways and how these interactions influence cell fate decisions such as proliferation, differentiation, and apoptosis. Overall, studying the effects of TCL-1B4 inhibitors deepens our knowledge of intracellular signaling regulation and the molecular mechanisms that maintain cellular function and balance.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine inhibits protein kinase C, which could be responsible for phosphorylation events that activate TCL-1B4, leading to the functional inhibition of TCL-1B4.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which may signal upstream of TCL-1B4. By inhibiting PI3K, it can lead to diminished activation of TCL-1B4.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is another PI3K inhibitor, working similarly to wortmannin, potentially reducing phosphorylation and subsequent activity of TCL-1B4.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits mTOR, which is involved in a signaling pathway that could regulate the activity of TCL-1B4, leading to its functional inhibition.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 inhibits MEK, which is part of the MAPK/ERK pathway; this inhibition can limit the activity of downstream proteins including TCL-1B4.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 functions similarly to PD98059 by inhibiting MEK in the MAPK/ERK pathway, leading to decreased activation of TCL-1B4.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 inhibits JNK, potentially restricting the activity of TCL-1B4 if JNK is involved in the same signaling pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 targets and inhibits p38 MAP kinase, which might interact with the same pathway as TCL-1B4, leading to its functional inhibition.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$92.00
$223.00
30
(1)

PP2 inhibits Src family kinases, which could phosphorylate and activate TCL-1B4, thereby inhibiting its function through reduced activation.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib inhibits Src family kinases as well as Bcr-Abl, which may regulate signaling pathways involving TCL-1B4, thus inhibiting TCL-1B4's activity.